The gut microbiome possesses a diverse range of biological properties that play a role in maintaining host health and preventing disease. Gut microbial metabolites, including short-chain fatty acids, natural purine nucleosides, ellagic acid derivatives, and tryptophan metabolites, have been observed to have complex and multifaceted roles in the gut and in wider body systems in the management of disease, including cancer. Triple-negative breast cancer is the most aggressive subtype of breast cancer, with restricted treatment options and poor prognoses. Recently, preclinical research has investigated the antiproliferative potential of gut microbial metabolites against this type of breast cancer with promising results. However, little is understood about the mechanisms of action and molecular pathways driving this antiproliferative potential. Understanding the complex mechanisms of action of gut microbial metabolites on triple-negative breast cancer will be instrumental in the investigation of the combined administration with standard chemotherapeutic drugs. To date, there is a paucity of research studies investigating the potential synergistic interactions between gut microbial metabolites and standard chemotherapeutic drugs. The identification of synergistic potential between these compounds may provide alternate and more effective therapeutic options in the treatment and management of triple-negative breast cancer. Further investigation into the mechanistic action of gut microbial metabolites against this breast cancer subtype may support the administration of more cost-effective treatment options for breast cancer, with an aim to reduce side effects associated with standard treatments. Additionally, future research will aim to identify more potent metabolite–drug combinations in the mitigation of triple-negative breast cancer progression and metastasis.
肠道微生物组具有多种生物学特性，在维持宿主健康和预防疾病方面发挥着重要作用。肠道微生物代谢产物，包括短链脂肪酸、天然嘌呤核苷、鞣花酸衍生物和色氨酸代谢物，已被观察到在癌症等疾病管理中，在肠道及更广泛的机体系统中扮演着复杂且多方面的角色。三阴性乳腺癌是乳腺癌中最具侵袭性的亚型，其治疗选择有限且预后较差。近期，临床前研究探讨了肠道微生物代谢产物对此类乳腺癌的抗增殖潜力，并取得了令人鼓舞的结果。然而，对于驱动这种抗增殖潜力的作用机制和分子通路，目前了解甚少。理解肠道微生物代谢产物对三阴性乳腺癌的复杂作用机制，将有助于研究其与标准化疗药物的联合给药。迄今为止，关于肠道微生物代谢产物与标准化疗药物之间潜在协同相互作用的研究尚显不足。识别这些化合物之间的协同潜力，可能为三阴性乳腺癌的治疗和管理提供替代性且更有效的治疗选择。进一步研究肠道微生物代谢产物对抗此类乳腺癌亚型的作用机制，可能支持采用更具成本效益的乳腺癌治疗方案，旨在减少与标准治疗相关的副作用。此外，未来的研究将致力于识别更有效的代谢物-药物组合，以减缓三阴性乳腺癌的进展和转移。
Guardians in the Gut: Mechanistic Insights into a Hidden Ally Against Triple-Negative Breast Cancer
肿瘤(癌症)患者之家